| A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3. | |
| | |
MedLine Citation:
|
PMID: 23183282 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Zesiewicz et al.(1) reported that varenicline improved ataxia in patients with spinocerebellar ataxia type 3 (SCA3) with excellent tolerance. We used open-label varenicline in a similar dosing schedule from 2 weeks to greater than 6 months in 7 patients with ataxia (3 SCA3, 1 multiple system atrophy with cerebellar features, 3 ataxia of unknown etiology). |
| | |
Authors:
|
Barbara S Connolly; L K Prashanth; Binit B Shah; Connie Marras; Anthony E Lang |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Neurology Volume: 79 ISSN: 1526-632X ISO Abbreviation: Neurology Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-27 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: United States |
Other Details:
|
Languages: eng Pagination: 2218 Citation Subset: AIM; IM |
Affiliation:
|
Toronto. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 7T MRI of spinal cord injury.
Next Document: Early thalamic lesions in patients with sleep-potentiated epileptiform activity.